Tyme Technologies Offers Incredible Risk-Reward

Dec. 07, 2021 6:47 PM ETSyros Pharmaceuticals, Inc. (SYRS)46 Comments


  • Tyme Technologies recently reported their Q2 earnings that revealed the company only burned roughly $5M in cash with about $97M left in the bank.
  • The small-cap sell-off has pushed the share price to fresh 52-week lows. I believe TYME has an incredible risk-reward at these prices.
  • I review some of the company’s updates and point out a few bullish highlights for investors. In addition, I discuss some of my lingering downside risks for TYME.
  • I update investors on my strategy for managing my TYME position and how I intend to take advantage of the sell-off.

Concept of balancing Reward versus Risk in business and life"n - 3d illustration

http://www.fotogestoeber.de/iStock via Getty Images

Tyme Technologies (TYME) had a productive second fiscal quarter with the company moving forward on their key strategic initiatives. Tyme has a novel platform technology that has developed their flagship product, SM-88, which has verified activity in

This article was written by

Biologics profile picture
Diagnosing the market to compound capital in the healthcare sector.

After years of working in the medical field, I have developed a passion for biotech and lifesaving therapies. Now, I am a full-time healthcare investor who is in search of the next breakthrough therapy, device, or pharmaceutical. My trade focus is around catalysts and potential acquisitions. In addition, I provide a marketplace service, Compounding Healthcare through Seeking Alpha.

Disclosure: I/we have a beneficial long position in the shares of TYME either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (46)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.